ProNAi To Present Phase II Clinical Data For New Cancer DrugProNAi Therapeutics Inc., a developer of drugs that target cancer by interfering with cancer cells' DNA, announced that data from its ongoing Phase II clinical study of its drug candidate PNT2258 will be presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans Dec. 7-10.
ProNAi Presents Cancer Drug Results, Expands Management TeamProNAi Therapeutics Inc., a cancer drug development company, said last week that it had concluded its initial human clinical trial of PNT2258, a new type of nucleic acid drug.

More From CBS Detroit

Best Cooking Classes In DetroitLearn how to whip up some wonderful dishes while having fun!
5 Bucket List Items To Cross Off In DetroitThe “must-do” items for anyone making a trip to Detroit.
Best Spots For A Quick Lunch In Downtown DetroitThese places will get you in and out.

Watch & Listen LIVE